TILS.L Regulatory News (TILS)

Tiziana Life Sciences PLC

("Tiziana" or the "Company")

Grant of options - Director's dealing

London, 31 August 2017 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announces that the Remuneration Committee proposed and the Board has awarded the following options on 30 August 2017.

Dr Kunwar Shailubhai, the Company's Chief Executive Officer and Chief Scientific Officer, has been awarded options over 400,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 159.5 pence per share. The options will vest in equal tranches over four years beginning on the date of grant. Dr Shailubhai already holds 300,000 options at an exercise price of 50p pursuant to an award made on 25 June 2014 (of which 200,000 options are vested and 100,000 remain subject to vesting conditions).

A further 168,000 options over ordinary shares in the capital of the Company were granted by the Company to staff members on the same terms and on the same date.

The Company's issued share capital comprises 123,827,938 ordinary shares of 3p each.

Including the grants noted above, the Company has granted options over a total of 10,717,403 ordinary shares of which 4,752,500 are vested at exercise prices between 15p and £1.25p per share and 5,964,903 remain subject to vesting conditions (at potential exercise prices ranging from 15p to £1.925 per share). In addition warrants to subscribe for a total of 4,239,579 ordinary shares at exercise prices between 50p and £2.50 are outstanding.

Therefore the fully diluted issued share capital of the Company is 138,784,920 ordinary shares (assuming all options and warrants, vested and unvested, exercised and exercisable, were converted).

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

For more information go to http://www.tizianalifesciences.com